MacroChem Presents EcoNail(TM) Clinical Data at Society for Investigative Dermatology Annual Meeting (1)
06 Mai 2005 - 2:30PM
PR Newswire (US)
MacroChem Presents EcoNail(TM) Clinical Data at Society for
Investigative Dermatology Annual Meeting (1) LEXINGTON, Mass., May
6 /PRNewswire/ -- Thomas Chan, PhD, vice president of R&D and
chief technology officer of MacroChem Corporation (NASDAQ:MCHM),
will present data from the Company's Phase I human safety and
tolerability study of EcoNail, at 11 AM today at the 66th annual
meeting of the Society for Investigative Dermatology (SID). The SID
meeting is being held at the America's Convention Center in St.
Louis, MO, May 4 through 7. (Photo:
http://www.newscom.com/cgi-bin/prnh/20050506/NYF036 ) EcoNail is
MacroChem's patented antifungal lacquer that contains econazole and
SEPA(R), the Company's proprietary enhancer. Econazole effectively
inhibits in vitro growth of the fungi that commonly cause a nail
infection known as onychomycosis, which affects more than 30
million people in the U.S. In a poster presentation titled,
"EcoNail lacquer in patients with severe onychomycosis: Safety,
local tolerability, and systemic exposure," Dr. Chan will discuss
results from MacroChem's recently completed human safety and
tolerability study. Data from this study show that EcoNail was well
tolerated and warrants advancement to efficacy trials. In addition
to the study data, photographs of the target toenail from the first
14 completed patients were evaluated by independent dermatologists.
The poster presentation includes photographs of toenails from 5 of
those completed patients judged to have shown initial signs of nail
improvement after either 12 or 18 weeks of treatment with EcoNail.
"I am pleased that Dr. Chan is able to share these encouraging data
with the scientific community," said Robert J. DeLuccia, MacroChem
president and CEO. "The next step in the EcoNail development plan
is a formal efficacy study, and we are in active discussions with
prospective partners and working to secure the resources necessary
to advance the program." An abstract of the EcoNail poster
presentation is available on the MacroChem web site,
http://www.macrochem.com/ . About MacroChem MacroChem is a
specialty pharmaceutical company that innovates, develops and
commercializes topically administered pharmaceuticals to treat
important medical conditions. MacroChem is developing two products
containing its patented enhancer, SEPA(R): Opterone(R), a
SEPA-enhanced topical testosterone treatment for male hypogonadism;
and EcoNail. For more information on MacroChem, and its technology
and products, please visit our website at:
http://www.macrochem.com/ . Forward-Looking Statements With the
exception of historical information contained in this press
release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection and dependence on third parties for
development and licensing arrangements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. MacroChem undertakes no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.
(1) Editor's Note: Digital photographs of an EcoNail bottle and
EcoNail application to an infected toenail are available upon
request. http://www.newscom.com/cgi-bin/prnh/20050506/NYF036
http://photoarchive.ap.org/ DATASOURCE: MacroChem Corporation
CONTACT: Investor Contact: Bernard Patriacca of MacroChem
Corporation, VP/CFO, +1-781-862-4003, Media Contact: Donna LaVoie
of LaVoie Group for MacroChem Corporation, +1-781-96-0200 ext 103
Web site: http://www.macrochem.com/
Copyright
Macrochem (NASDAQ:MCHM)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Macrochem (NASDAQ:MCHM)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
Echtzeit-Nachrichten über Macrochem (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Macrochem (MM) News-Artikel